Fruehauf S, Breems D A, Knaän-Shanzer S, Brouwer K B, Haas R, Löwenberg B, Nooter K, Ploemacher R E, Valerio D, Boesen J J
Department of Medical Biochemistry, University of Leiden, The Netherlands.
Hum Gene Ther. 1996 Jun 20;7(10):1219-31. doi: 10.1089/hum.1996.7.10-1219.
Transfer of the multidrug resistance-1 (MDR1) gene into hematopoietic progenitor cells may reduce myelotoxicity of MDR1-related cytotoxic agents and therefore allow dose intensification. Mobilized peripheral blood progenitor cells (PBPC) can be obtained in ample quantity and are a suitable target cell population. CD34-selected PBPC samples (n = 6) were transduced with cell-free supernatant (SNT) of a cell line producing recombinant retrovirus containing the human MDR1 gene. Limiting-dilution long-term cultures were employed that allow continuous monitoring of stroma-adherent cobblestone areas (CA) and comparison of their frequency in a 5-log range over time. MDR1 provirus integration in CA-containing wells followed single-hit kinetics. According to Poisson statistics, proviral DNA was contained in 22% of unselected cobblestone area-forming cells (CAFC) at week 6, which represent primitive hematopoietic precursors. In comparison, 1.0 +/- 0.44% (mean +/- SEM) of week-6 CAFC were expressing P-glycoprotein at sufficient levels to convey vincristine resistance, suggesting low expression of the retroviral vector or splicing of the vector-drived mRNA in hematopoietic progenitor cells. Next we analyzed lineage-committed progenitors. The proviral DNA was detectable in 20-66% of colony-forming units granulocyte-macrophage (CFU-GM) while corresponding percentages (25-52%) of CD34+ PBPC were in the S/G2M phase of the cell cycle at the end of the transduction period. The proportion of vincristine-resistant CFU-GM was similar to the CAFC data and no significant differences were found between various MDR1-SNT transduction schedules whereas MDR1 co-cultivation, which served as a positive control, yielded significantly higher proportions of resistant colonies (5.3 +/- 1.4%, IL-3, 96 hr, p < or = 0.05). Assessment of rhodamine-123 (Rh-123) efflux in the myelo-monocytic progeny of MDR1-transduced cells mirrored the colony assay results in the SNT and co-cultivation groups. Less culture effort was required in the Rh-123 assay and functional characterization of the transferred P-glycoprotein was possible using cyclosporin A. Further development toward an effective MDR1 gene therapy should be facilitated by the CAFC assay, which allows estimation of the retroviral gene transfer frequency into primitive hematopoietic cells, and by the Rh-123 assay, which permits tractable side-by-side assessments of numerous MDR1 transduction protocols or different MDR1-SNT lots.
将多药耐药-1(MDR1)基因导入造血祖细胞可能会降低与MDR1相关的细胞毒性药物的骨髓毒性,从而实现剂量强化。动员的外周血祖细胞(PBPC)可以大量获取,是合适的靶细胞群体。用产生含人MDR1基因的重组逆转录病毒的细胞系的无细胞上清液(SNT)转导CD34分选的PBPC样本(n = 6)。采用有限稀释长期培养法,可连续监测基质黏附鹅卵石区域(CA),并比较其在5个对数范围内随时间的频率。含CA的孔中MDR1前病毒整合遵循单 hit 动力学。根据泊松统计,在第6周时,22%的未分选鹅卵石区域形成细胞(CAFC)含有前病毒DNA,这些细胞代表原始造血前体。相比之下,第6周的CAFC中有1.0 +/- 0.44%(平均值 +/- 标准误)以足以赋予长春新碱抗性的水平表达P-糖蛋白,这表明逆转录病毒载体在造血祖细胞中的表达较低或载体驱动的mRNA发生了剪接。接下来我们分析了定向祖细胞。在20 - 66%的粒细胞-巨噬细胞集落形成单位(CFU-GM)中可检测到前病毒DNA,而在转导期结束时,相应比例(25 - 52%)的CD34+ PBPC处于细胞周期的S/G2M期。长春新碱抗性CFU-GM的比例与CAFC数据相似,不同的MDR1-SNT转导方案之间未发现显著差异,而作为阳性对照的MDR1共培养产生的抗性集落比例显著更高(5.3 +/- 1.4%,IL-3,96小时,p≤0.05)。对MDR1转导细胞的髓单核细胞后代中罗丹明-123(Rh-123)外流的评估反映了SNT和共培养组的集落测定结果。Rh-123测定所需的培养工作较少,并且使用环孢素A可以对转移的P-糖蛋白进行功能表征。CAFC测定有助于估计逆转录病毒基因向原始造血细胞的转移频率,Rh-123测定允许对众多MDR1转导方案或不同的MDR1-SNT批次进行易于处理的并排评估,这应有助于向有效的MDR1基因治疗的进一步发展。